Technical success is not commercialization readiness. Before committing more capital, an ophthalmic leadership team should be able to answer seven questions with evidence: who benefits, compared with what, under which conditions, with which users and workflow, at what economics, through which regulatory path, and which uncertainty must be resolved next.
1. Which patient problem matters enough to change practice?
Name the intended patient and the specific clinical burden. Then describe the current alternatives. “Better vision” is too broad to guide development; the decision needs a benefit that patients notice and clinicians can assess. The comparison should include treatment burden and trade-offs as well as the primary endpoint.
2. What does the evidence actually establish?
Separate feasibility from repeatable clinical benefit. Look at study design, patient selection, follow-up, missing outcomes and the difficult cases. In early wavefront-guided LASIK work, the promising results and incomplete correction of higher-order aberrations were both important findings.1 A development plan should say which claim is demonstrated and which remains a hypothesis.
3. Can representative clinicians use it reliably?
A device or procedure has to work in the hands of its intended users, in its intended environment. FDA human-factors guidance emphasizes representative users, realistic use conditions and training aligned with actual practice.2 Ask what could go wrong in preparation, treatment and follow-up, and whether the training and workflow have been tested rather than merely described.
4. What would cause repeat adoption?
An enthusiastic first use is not a commercial pattern. Define who selects patients, who explains benefits and limitations, how the team is trained, and who reviews outcomes. Repeat use depends on a reliable experience across those steps. This is a working commercial hypothesis, which should be checked with prospective users and early accounts.
5. Can delivery work economically?
Estimate the full cost and time of treatment: equipment, consumables, staff, training, follow-up and any rework. Then test the price and payment assumptions in the intended market. Do not treat a large eligible population as evidence of demand. A useful model exposes which adoption rate, utilization and margin assumptions change the decision.
6. What is the route for this intended use and market?
Write down the intended use, jurisdiction, product classification questions and evidence expected for the next regulatory interaction. The pathway can differ by market and product. A clinical investigation authorization is not a commercial authorization; the distinction matters in external communication as well as the development plan. Regulatory specialists should verify the specific pathway before a commitment.
7. Which uncertainty should the next milestone resolve?
Choose the question whose answer could change the decision to invest, partner, develop or launch. Define the evidence, decision threshold, owner and timing before starting the work. The result may justify moving forward, changing the product or stopping. An explicit decision is more useful than another encouraging but inconclusive experiment.
Commercialization readiness is a sequence of evidence-backed decisions, not a single launch date.
My selected work illustrates how scientific findings, development limits and delivery decisions connect. The six-question approach provides a shorter discussion framework. If your team is facing a specific product or portfolio decision, see the company advisory perspective or send a short, non-confidential brief.